Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Recent advances in targeted protein degradation and kinase modulation highlight therapeutic versatility across disease areas. Keap1-based degraders eliminate oncogenic KRAS and androgen receptor in cancer, antifolate–idasanutlin hybrids degrade Plasmodium falciparum DHFR-TS to overcome antifolate resistance, and PLK1 inhibition suppresses NLRP3 inflammasome activation to improve cardiac outcomes. Together, these innovations expand degrader and kinase-targeting strategies into oncology, infectious disease, and inflammatory cardiology.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: